Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire

NCT03614689 is registered in ClinicalTrials.gov with Geneplus-Beijing Co. Ltd. as lead sponsor.

NCT NCT03614689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire
Lead sponsor
Geneplus-Beijing Co. Ltd.
Phase
Observational
Overall status
Unknown status
Start date
November 25, 2017
Completion date
December 31, 2024
Enrollment
104 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer